Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
TCBP - TC BioPharm (Holdings) plc
Market Cap 3.21M P/E - EPS this Y - Ern Qtrly Grth -
Income -8.59M Forward P/E -0.15 EPS next Y - 50D Avg Chg 12.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -81.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -97.00%
Recommedations 2.00 Quick Ratio 0.46 Shares Outstanding 572.02K 52W Low Chg 64.00%
Insider Own 0.01% ROA -108.92% Shares Float 98.41M Beta 0.09
Inst Own 1.77% ROE -1,217.48% Shares Shorted/Prior 66.34K/30.24K Price 0.68
Gross Margin - Profit Margin - Avg. Volume 570,343 Target Price -
Oper. Margin - Earnings Date - Volume 1,838,184 Change 14.29%
Healthcare | Biotechnology | United Kingdom
About TC BioPharm (Holdings) plc

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

TC BioPharm (Holdings) plc News
12/20/24 TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients
12/18/24 TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend
12/18/24 EXCLUSIVE: Penny Stock TC BioPharm Proposes Special Stock Dividend
12/11/24 TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
12/04/24 TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial
11/12/24 TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant
10/30/24 TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements
10/25/24 TCBP Responds to False Social Media Claim
10/22/24 TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic
10/03/24 TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening
09/25/24 TCBP Announces Site Opening of Guys and St. Thomas Hospital
09/24/24 TCBP to Present at the 2024 ThinkEquity Conference in NYC
09/20/24 /C O R R E C T I O N -- TC BioPharm/
09/12/24 TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial
09/09/24 TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
09/05/24 TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
09/03/24 Sector Update: Health Care Stocks Decline Late Afternoon
09/03/24 TCBP Announces Dosing of 5 New Patients in ACHIEVE
08/29/24 TC BioPharm secures European patent for cancer treatment
08/28/24 TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Randall Mark Edward 10% Owner 10% Owner Nov 30 Buy 5 70,000 350,000 382,963 01/11/23
Randall Kenneth Edward 10% Owner 10% Owner Nov 30 Buy 5 70,000 350,000 382,963 01/11/23
Renaissance Capital Partners L... 10% Owner 10% Owner Nov 30 Buy 5 70,000 350,000 136,834 01/11/23
Randall Kenneth Edward 10% Owner 10% Owner May 24 Buy 1.15 20,803 23,923 100,418 07/14/22